Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2028642 | PMC |
| http://dx.doi.org/10.1136/bmj.1.5078.1034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anagen Effluvium in a Child Misusing Methotrexate: A Case Report With Dermoscopic Findings.
Pediatr Dermatol
March 2025
Department of Dermatology, Ankara Etlik City Hospital, Ankara, Turkey.
Anagen effluvium is a rare adverse effect of methotrexate therapy, generally associated with high-dose regimens. We report a 12-year-old girl who developed abrupt hair loss 1 week after inadvertently taking methotrexate 15 mg daily for five consecutive days (total 75 mg), without other signs of systemic toxicity. Trichoscopic examination and trichogram findings confirmed methotrexate-induced anagen effluvium, and spontaneous hair regrowth occurred after 2 months.
View Article and Find Full Text PDFSignal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database.
Front Pharmacol
February 2025
Department of Pharmacology, The First People's Hospital of Yancheng, Yancheng, Jiangsu, China.
Background: Ripretinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GISTs) who have previously received treatment with at least three kinase inhibitors. The objective of this study was to evaluate adverse events(AEs) associated with ripretinib using data from the FDA Adverse Event Reporting System (FAERS) database.
Methods: Individual case safety reports (ICSRs) related to of ripretinib from 2020 Q2 to 2024 Q2 were extracted from the FAERS database.
Effectiveness of Extracellular Vesicle Application in Skin Aging Treatment and Regeneration: Do We Have Enough Evidence from Clinical Trials?
Int J Mol Sci
March 2025
Department of Human Epigenetics, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.
In recent years, there has been a dynamic development in therapies utilizing extracellular vesicles (EVs) including exosomes. Therefore, we have conducted an analysis of the scientific literature to verify the current state of knowledge about these therapies. A total of 12 clinical studies were analyzed, covering the use of EVs in treating skin aging, acne scars, alopecia, and wound healing.
View Article and Find Full Text PDFAnti-Hair Loss Effect of Veratric Acid on Dermal Papilla Cells.
Int J Mol Sci
March 2025
Biospectrum Life Science Institute, Sinsu-ro, Suji-gu, Yongin-City 16827, Gyeonggi-Do, Republic of Korea.
The activation of hair follicle dermal papilla cells (HFDPCs), a critical target of hair loss relief, can be achieved through the upregulation of proliferation, the stimulation of hair inducibility, and the inhibition of cellular senescence. Veratric acid (VA) is a major benzoic acid found in fruits and vegetables. The biological activity of VA on HFDPCs remains to be elucidated.
View Article and Find Full Text PDFDual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata-A Small Retrospective Cohort Study.
Diagnostics (Basel)
February 2025
Discipline of Dermatology, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania.
Atopic dermatitis (AD) and alopecia areata (AA) frequently coexist due to shared immune-mediated mechanisms. Treatments targeting AD, including Janus kinase (JAK) inhibitors and dupilumab, may impact AA outcomes in unpredictable ways. This study aims to evaluate the effects of advanced therapies on patients with concurrent AD and AA to inform treatment strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!